NSCLC

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

NSCLC
Dec 24, 2024, 17:55 | Blog
Layth Mula-Hussain: Prognostic factors and survival in patients with NSCLC and brain metastases
Layth Mula-Hussain, Radiation Oncologist and Assistant Professor at Dalhousie University, shared on LinkedIn: “Recently released.…
Dec 24, 2024, 00:18 | Blog
Jordi Remon: 2024 - Fortunately it is difficult to merge all treatments for NSCLC
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared a post on X: "2024: Fortunately it…
Dec 23, 2024, 20:29 | Science
Alba Fiorentino: An oligometastatic lung cancer case report with a durable complete metabolic response
Alba Fiorentino, Associate Professor of Radiation Oncology at LUM University of Medicine, shared a post…
Dec 23, 2024, 12:47 | Science
Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
A recent paper by Benjamin Besse, Director of Clinical Research at the Gustave Roussy Institute,…
Dec 22, 2024, 17:26 | Science
Andrea De Giglio: The prognostic role of STK11 mutations in advanced NSCLC treated with first-line IO
Andrea De Giglio, Junior Assistant Professor at University of Bologna, posted on X about recent…
Dec 22, 2024, 13:45 | Science
Details on uncommon EGFR mutations in NSCLC from Dr. Alfredo Addeo
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Dec 22, 2024, 10:44 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Dec 21, 2024, 22:35 | Blog
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Santiago Viteri, Medical Director at UOMi Cancer Center and Chief Executive Officer at Pratia Sirius,…
Dec 20, 2024, 16:39 | Drugs
FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC
On December 18, 2024, The FDA has approved ensartinib for the treatment of ALK-positive, locally…
Dec 20, 2024, 14:19 | Science
Ravi Parikh: Predicting immunotherapy response in non-small cell lung cancer
Ravi Parikh, Director of Human-Algorithm Collaboration Lab at Winship Cancer Institute of Emory University, shared…
Dec 20, 2024, 10:11 | Blog
Giannis Mountzios: End of story for anti-PD1/TIGIT?
Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at HENRY DUNANT Hospital…
Dec 19, 2024, 12:01 | Insight
Remon Jordi Discusses Advances in Thoracic Oncology at ESMO Asia 2024
Mediamedic shared a post on LinkedIn: “ESMO Asia 2024, Jordi Remon Masip Highlights Key Thoracic…
Dec 19, 2024, 07:24 | Drugs
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage…
Dec 18, 2024, 06:47 | Insight
Lauren Averett Byers has been awarded the 2025 Edith and Peter O’Donnell Award in Medicine
Lauren Averett Byers was honored for Groundbreaking Contributions to Small Cell Lung Cancer Research and…
Dec 17, 2024, 23:14 | Science
Stephen V Liu: Resistance and identification of synthetic lethal targets in KRAS STK11 NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, posted on X: "Fascinating work…
Dec 17, 2024, 16:18 | Insight
Update on U.S. Regulatory Review of Subcutaneous Amivantamab
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a…
Dec 17, 2024, 12:59 | Insight
Highlights from IASLC HTTR 2024
HHTR 2024 took place from December 13-15, 2024, at the Hilton Washington DC National Mall…
Dec 16, 2024, 19:13 | Blog
Suresh S. Ramalingam on insurance coverage challenges for Keytruda in NSCLC Patients
Suresh S. Ramalingam, Executive Director of Winship Cancer Institute of Emory University, shared a post…
Dec 16, 2024, 08:33 | Insight
Jarushka Naidoo: KN867 trial shows no EFS benefit for SBRT+Pembro in NSCLC
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin (Ireland), posted the following on X: “ESMO…
Dec 15, 2024, 14:35 | Blog
PROSPECT-Lung Trial: Evaluating Optimal Timing of Immunotherapy for Operable Non-Small Cell Lung Cancer
Innovative Study Led by Dr. Raid Aljumaily Aims to Revolutionize Lung Cancer Treatment and Enhance…
Dec 13, 2024, 16:57 | Insight
Akhil Santhosh: IO added to CTRT doesn't work in stage 3 NSCLC
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute and Post DM…
Dec 12, 2024, 13:14 | Blog
Razelle Kurzrock: Targeting NRg1 fusions
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Dec 11, 2024, 17:56 | Insight
Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…
Dec 11, 2024, 17:44 | Blog
Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
Mediamedic shared a post on LinkedIn: "Editor’s Note: EGFR mutations are among the most common…
Dec 11, 2024, 15:48 | Insight
Tumor Methylation Burden in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics
"One of the emerging biomarkers in lung cancer that is gaining attraction is Tumor Methylation…
Dec 11, 2024, 10:33 | Blog
Pemetrexed plus platinum ± pembrolizumab in untreated metastatic nonsquamous NSCLC
ESMO shared on X: "For Annals of Oncology Anniversary we highlight this 2023 top-cited paper:' Pemetrexed…
Dec 11, 2024, 10:30 | Insight
David D. W. Lee: Proud to be a part of the Pan-Asian adapted ESMO Clinical Practice Guideline
David D. W. Lee, Consultant Clinical Oncologist at the University of Malaya Medical Centre and…
Dec 10, 2024, 04:30 | Insight
Texas Lung Cancer Conference 2025
Texas Lung Cancer Conference 2025 will be held from April 10-12, 2025 at Austin, Texas.…
Dec 9, 2024, 14:27 | Insight
Sanjay Popat: The Pan-Asian adapted ESMO Clinical Practice Guidelines for Oncogene Addicted Metastatic NSCLC
Sanjay Popat, Professor at The ICR and Thoracic Oncologist at The Royal Marsden NHS Foundation Trust,…
Dec 8, 2024, 04:47 | Insight
Yvonne Diaz: Study shows family history links to lung cancer risk
Yvonne Diaz, Director of Global Media Relations and Social Media at EY, shared on X:…
Dec 8, 2024, 04:47 | Insight
Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…
Dec 8, 2024, 02:56 | Insight
Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X:…
Dec 7, 2024, 11:04 | Blog
Lorenza Rimassa: Patient Advocate on Immunotherapy Choices in HCC and NSCLC at ESMO Asia 2024
Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared a post on X: "Patient…
Dec 5, 2024, 11:01 | Insight
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for…
Dec 4, 2024, 14:36 | Blog
2024 Marks The 20th Anniversary of The Discovery of EGFR in NSCLC
May 2024 Marks The 20th Anniversary of the Publication of Papers on The Role of…
Dec 4, 2024, 00:00 | Blog
ESMO - Practice-changing publications in NSCLC and endometrial cancer critically reviewed by leading experts
ESMO shared on LinkedIn: " Practice-changing publications in NSCLC (LAURA trial) and endometrial cancer (RUBY trial)…
Dec 3, 2024, 17:22 | Insight
Actions to Boost Lung Cancer Research and Innovation
Giannis Mountzios, Consultant Medical Oncologist of the 2nd Oncology Department and Clinical Trials Unit at…
Dec 3, 2024, 03:53 | Blog
Amol Akhade: Insights into Resistance Mechanisms for EGFR TKI in NSCLC
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance, posted the…
Dec 2, 2024, 20:05 | Insight
Xiuning Le: RTK fusion-mediated resistance to EGFR-TKI in EGFR-mutated NSCLC
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared…
Dec 2, 2024, 10:22 | Blog
Tejas Patil: The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in non-small cell lung cancer
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, posted on X about recent…
Nov 30, 2024, 22:23 | Blog
Aakash Desai: Real-World Data on Dabrafenib-Trametinib for BRAF V600E-Mutated NSCLC
Aakash Desai, Associate Director and Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X:…
Nov 30, 2024, 19:13 | Insight
Vivek Subbiah: ADC Target Expression and Interstitial Lung Disease in NSCLC
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…
Nov 27, 2024, 19:58 | Insight
Stephen Liu: Phase III SKYSCRAPER-01 study is negative for OS at final analysis
Stephen Liu, Associate Professor of Medicine at Georgetown University, shared a post on X: "Press…
Nov 27, 2024, 16:05 | Opinion
Novel scenarios for unresectable stage III NSCLC discussed by Antonio Nuccio and Matteo Sepulcri
Roberto Ferrara, Medical Oncologist, Researcher in Thoracic Oncology and Molecular Immunology, at Vita-Salute San Raffaele…
Nov 26, 2024, 15:12 | Insight
Management of Stage III Non–Small Cell Lung Cancer
Jame Abraham, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared…
Nov 26, 2024, 11:27 | Blog
Navneet Singh: The importance of predictive biomarker testing in all adenocarcinoma/non-squamous NSCLC
Navneet Singh, Thoracic Medical Oncologist and a Professor at PGIMER, shared a post by IASLC…
Nov 25, 2024, 14:38 | Blog
Estela Rodriguez: Discussion on best 1st line therapy for ALK+ NSCLC at MATOS24
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of…
Nov 25, 2024, 14:26 | Blog
Shashi Shankar: Understanding Barriers to Biomarker Testing is a Bold Step Towards Equity in Care
Aakash Desai, Associate Director and Assistant Professor at UAB O'Neal Comprehensive Cancer Center, reshared the…
Nov 25, 2024, 08:02 | Blog
Jarushka Naidoo: Memorial Sloan Kettering Cancer Center reunion at Gathering Around Cancer 2024
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin, shared a post on X: "Memorial Sloan…
Nov 24, 2024, 18:32 | Insight
Estela Rodriguez: A great overview of treatment paradigm for EGFR20ins NSCLC by Zosia Piotrowska
Estela Rodriguez, Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, posted…
Nov 23, 2024, 12:01 | Blog
Aakash Desai: Bridging the gap between clinical advancements and real-world application
Aakash Desai, Associate Director and Assistant Professor at UAB O'Neal Comprehensive Cancer Center, shared a…
Nov 21, 2024, 12:57 | Insight
Navneet Singh: Molecular testing in all stages of NSCLC
Navneet Singh, A Thoracic Medical Oncologist and a Professor at PGIMER, shared an article on…
Nov 20, 2024, 19:12 | Blog
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
IASLC (The International Association for the Study of Lung Cancer) shared a post on X:…
Nov 20, 2024, 16:38 | Insight
Herbert Loong: NTRK gene fusion testing in the management of NSCLC
Herbert Loong, Chair-Elect of the International Affairs Committee of ASCO, shared a post on X…
Nov 20, 2024, 15:19 | Insight
Eric Lim: Immunotherapy - before, after or both?
Eric Lim, Professor of Thoracic Surgery at Royal Brompton Hospital, shared his recent article on…
Nov 20, 2024, 11:30 | Insight
Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment
Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…
Nov 19, 2024, 13:43 | Insight
Highlights from New York Lung Cancers Symposium 2024 by Stephen V Liu
The New York Lung Cancers Symposium 24 (NYLung24) took place on 16th of November 2024,…
Nov 19, 2024, 10:18 | Insight
Anita McGrath’s Advocacy Journey in Lung Cancer - IASLC
IASLC shared a post on X: "Anita McGrath’s Advocacy Journey in Lung Cancer.   Anita McGrath,…
Nov 17, 2024, 07:43 | Blog
Tanja Obradovic: Important milestone for Dizal Pharmaceutical with sunvozertinib NDA submission
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Nov 16, 2024, 06:55 | Blog
Jill Feldman: Updated living guidelines for treating stage IV NSCLC with driver alterations
Jill Feldman, Co-Founder EGFR Resisters and a member of the programmatic panel for the Department…
Nov 14, 2024, 13:11 | Blog
American Society of Clinical Oncology's new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Check out our new…
Nov 14, 2024, 12:14 | Blog
Targeted therapy advancements in NSCLC - ACS Journal Cancer
ACS Journal Cancer posted the following on X: “Targeted therapy plays an important role for…
Nov 13, 2024, 23:35 | Insight
Raffaele Colombo: New BLA submitted for patients with EGFR-m NSCLC
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article on X: “Dato-DXd…
Nov 13, 2024, 16:08 | Blog
Evolving role of Radiation in early stage NSCLC by Dr. Annalisa Nardone
Stephen V Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown…
Nov 12, 2024, 19:34 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Nov 12, 2024, 14:55 | Blog
Lissandra Dal Lago: Discussing Innovative endpoints for the development of new treatment strategies in Geriatric Oncology
Lissandra Dal Lago, Chair EORTC Older Adult Council at European Organisation for Research and Treatment of…
Nov 11, 2024, 17:12 | Blog
Stephen Liu: The Importance of Waiting for Biomarker Results in NSCLC
Stephen Liu, Associate Professor of Medicine at Georgetown University, shared a post on X: "It…
Nov 11, 2024, 04:17 | Insight
Advantage of SBRT over Surgery for early-stage NSCLC, study by Jochem Kaas
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at…
Nov 9, 2024, 18:21 | Blog
Aakash Desai Discusses Key Findings on ADCs in NSCLC Treatment
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted the following on LinkedIn: “In…
Nov 9, 2024, 18:17 | Blog
Katsuaki Maehara: Using targeted NGS analysis for EGFR classical mutations in NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “EGFR classical mutated NSCLC Frequency…
Nov 9, 2024, 11:23 | Blog
European Organisation for Research and Treatment of Cancer webinar on innovative study designs for older adults
EORTC - European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:…
Nov 8, 2024, 20:09 | Insight
Narjust Florez: Sarah Waliany on mechanisms of resistance to first-line vs. later-line Alectinib for ALK and NSCLC
Narjust Florez, Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center, shared a post on…
Nov 8, 2024, 19:08 | Blog
Shahrin Ahmed: Looking back at the progress made in cell and gene therapy during LCAM 2024
Shahrin Ahmed, Medical specialist in oncology at the Canadian Cancer Society, shared a post on…
Nov 8, 2024, 13:58 | Blog
Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials
Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent…
Nov 3, 2024, 16:27 | Insight
Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO
Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a…
Nov 3, 2024, 13:55 | Insight
Highlights from JLCS24 by Stephen Liu
The 65th Annual Meeting of the Japanese Lung Cancer Society was held at PACIFICO Yokohama…
Nov 2, 2024, 05:07 | Blog
Razelle Kurzrock: Expanding HER2 horizons - Implications for NSCLC and beyond
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Nov 1, 2024, 17:46 | Blog
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:…
Oct 31, 2024, 09:03 | Insight
Jarushka Naidoo: Maintenance Pembrolizumab with or without Olaparib for Advanced Squamous NSCLC
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin, shared a post on X about…
Oct 29, 2024, 22:00 | Blog
Jill Feldman: Hope and reality are NOT mutually exclusive
Jill Feldman, Co-Founder EGFR Resisters, shared a post by Katsuaki Maehara, Director of Medical Education…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 29, 2024, 10:11 | Insight
Stephen V Liu: Real-world 5-year survival with first line pembrolizumab in PD-L1 high NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Oct 28, 2024, 14:45 | Blog
Stephen V Liu: Immunotherapy for NSCLC discussed at the Emirates Oncology Society meeting
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Oct 26, 2024, 11:11 | Insight
Giuseppe Banna: Key considerations for implementing the LAURA study findings into clinical practice
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on…
Oct 25, 2024, 16:19 | Insight
EGFR-mutated oligo-organ metastatic NSCLC, summarised by Katsuaki Maehara
Katsuaki Maehara ,Director of Medical Education Colleagues, shared a post on X: " EGFR-mutated oligo-organ…
Oct 25, 2024, 13:51 | Blog
Drew Moghanaki: Standard of care for stage III NSCLC remains immunotherapy after CRT
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA,…
Oct 24, 2024, 13:05 | Blog
Concurrent thoracic radiotherapy improves the PFS and OS with acceptable toxicity in EGFR-mutated NSCLC
Gustavo Viani shared a post on Linkedin: ''Concurrent thoracic radiotherapy improves the PFS and OS…
Oct 23, 2024, 18:22 | Insight
Stephen Liu: What role does surgery play for patients with stage IV NSCLC?
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a post…
Oct 22, 2024, 15:54 | Blog
Chul Kim: Jennifer A. Marks on KRAS mutant NSCLC at DC Lung 24
Chul Kim, Associate Professor at Georgetown University, shared a post on X: "Great talk by…
Oct 21, 2024, 08:47 | Blog
Nagla Abdel Karim: Advances in molecular targets for NSCLC
Nagla Abdel Karim shared the following on X: “Mariam Alexander presents all about before &…
Oct 20, 2024, 19:15 | Insight
Gustavo Viani: Osimertinib post-CRT as the standard of care in unresectable stage III EGFR mutated NSCLC
Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital…
Oct 20, 2024, 17:47 | Drugs
Stephen V Liu: Long-term survival with nivolumab and ipilimumab in advanced NSCLC
Stephen V Liu shared on X: "Long-term survival (median f/u 73.7m) with nivolumab and ipilimumab…
Oct 20, 2024, 14:46 | Blog
Chul Kim: Neoadjuvant and perioperative chemoimmunotherapy in resectable NSCLC
Chul Kim shared on X: “Neoadjuvant and periop chemoimmunotherapy regimens have improved outcomes in resectable…
Oct 20, 2024, 11:34 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Oct 19, 2024, 15:57 | Insight
FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial
The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…
Oct 18, 2024, 13:52 | Insight
Hidehito Horinouchi: Oral Abstract Session 1 at ACLC24
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:…
Oct 18, 2024, 12:56 | Blog
Jonathan Spicer: Proud of our team’s results in minimally invasive lung resection
Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, shared a post on X:…
Oct 17, 2024, 16:04 | Insight
Estela Rodriguez: Novocure’s Optune Lua TTF (device) plus docetaxel or Immunotherapy for 2L NSCLC
Estela Rodriguez shared a post on X: "Its only Tuesday and we have another ⁦FDA…
Oct 17, 2024, 15:52 | Blog
Oncology Brothers: Last 4 weeks in Lung Cancer
Oncology Brothers shared a post on X: "Last 4 weeks in Lung Cancer: 1. PR:…
Oct 16, 2024, 17:00 | Insight
Biagio Ricciuti: 5-year update from the NADIM trial
Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et…
All: 521 Posts: 1 - 100
Special Coverage